carbamazepine + lamotrigine + phenytoin + valproic acid

This is a combination of four antiepileptic drugs (AEDs): carbamazepine, lamotrigine, phenytoin, and valproic acid. Each drug has a distinct mechanism of action and is used in the management of epilepsy and various seizure types. Carbamazepine and phenytoin are sodium channel blockers that reduce neuronal excitability by stabilizing inactive states of voltage-gated sodium channels. Lamotrigine also primarily acts as a sodium channel blocker but may have additional effects on glutamate release. Valproic acid has multiple mechanisms including increasing brain levels of gamma-aminobutyric acid (GABA), inhibiting voltage-gated sodium channels, and weakly attenuating T-type calcium channels. This combination would be considered polytherapy for refractory or complex epilepsy cases where monotherapy or dual therapy has failed. However, combining these agents increases the risk for pharmacokinetic interactions—carbamazepine and phenytoin induce hepatic enzymes that can lower serum concentrations of other AEDs; valproic acid inhibits certain metabolic pathways leading to increased levels (and potential toxicity) of some co-administered AEDs such as lamotrigine[1][5][6]. The use of all four together is rare due to high risk for adverse effects but may be seen in highly resistant epilepsy under specialist supervision.